FORM PTO-1449 (Rev. 2-32)

U.S. Department of Commerce Patent and Trademark Office

Attv.	Dock	t	No.	
Aug.	DOOK	•	140.	

Serial No.

00-830-A

09/887,182



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Vargeese et al.

Filing Date:

Group:

June 22, 2001

1623

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
$\mathcal{G}_{\mathcal{N}}$	1.	5,153,319	03/31/86	Caruthers et al	536	27	
	2.	5,132,418	06/18/84	Caruthers et al	536	27	
	3.	4,973,679	09/18/86	Caruthers et al	536	27	
	4.	5,686,599	05/02/95	Tracz	536 -	25.31	
	5.	5,804,683	05/05/95	Usman et al	435	113	
	6.	5,831,071	08/29/97	Wincott et al	536	25.31	
	7.	5,281,701	07/12/91	Winayak	536	25	
	8.	4,923,901	09/04/87	Koester and Coull	512	53	
	9.	5,723,599	03/22/95	Klem and Riley	536	25.3	
	10.	5,674,856	02/23/95	Kurukawa	514	44	
	11.	5,141,813	08/28/89	Nelson	428	402	
	12.	5,419,966	07/12/93	Reed	428	406	
	13.	4,458,066	03/24/81	Caruthers et al	536	27	
	. 14.	5,252,723	11/27/90	Bhatt	536	25.3	
	15.	4,987,071	12/03/86	Cech et al	435	91	
	16.	5,849,902	12/15/98	Arrow et al	36	24.5	
90	17.	5,989,912	12/15/98	Arrow et al	435	375	

EXAMINER ()~	ne	2	el		DATE CONSIDERED	13	JUNE 2003	

FORM	PTO-1449
(Rev. 2	2-32)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No.

Serial No.

00-830-A

09/887,182

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Vargeese et al.

Filing Date:

Group:

June 22, 2001

1623

gw	18.	5,834,186	06/02/95	George et al	435	6	
	19.	5,741,679	09/16/94	George et al	435	91.31	
	20.	5,589,332	05/09/94	Shih et al	435	6	
	21.	5,871,914	06/02/94	Nathan et al	435	6	
	22.	5,334,711	06/22/92	Sproat	536	24.5	
	23.	5,716,824	04/20/95	Beigelman et al	435	240.1	
	24.	5,627,053	05/02/95	Usman et al	435	91.1	
	25.	5,672,695	09/23/91	Eckstein et al	536	24.5	
gv.	26.	4,306,839	08/23/79	Pien	416	200 R	

FOREIGN PATENT DOCUMENTS

-		Document Number	Date	Country	Class	Subclass	Tran	slation
							Yes	No
(M)	27.	0 325,970	14.01.89	Europe				
1	28.	2,169,605 A	16.12.85	Japan (Yano et al)				
	29.	94/01446	29.06.93	WO/PCT (Reddy et al)				
	30.	280,968	10.07.83	Germany (Samuel P. Smith)				
	31.	97/42202	04.10.96	WO/PCT (Zhang et al.)				
	32.	92/07065	23.09.91	WO/PCT (Eckstein et al.)				
M	33.	93/15187	28.01.93	WO/PCT (Usman et al.)				

EXA	ıMı	NEF	₹
-----	-----	-----	---

DATE CONSIDERED

13 June 2003

FO	RM P	ГО-1449
(R	v. 2-3	32)

U.S. Department of Commerc Patent and Trademark Offic

Atty. I	Docket	No.
---------	--------	-----

н			
ı	Se	rial	No.

00-830-A

09/887,182



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Vargeese et al.

Filing Date:

Group:

June 22, 2001

				T****			
Sn	34.	97/26270	23.12.96	WO/PCT (Wincott et al.)			
VV	35.	00/24931	22.10.99	WO/PCT (Nathan et al.)	-		
	36.	00/26226	29.10.99	WO/PCT (Breaker et al.)			
	37.	98/27104	18.12.97	WO/PCT (Breaker et al.)			
	38.	99/29842	03.12.98	WO/PCT (Sullenger et al.)			
	39.	98/13526	26.09.97	WO/PCT (Arrow et al.)			
	40.	99/54459	19.04.99	WO/PCT (Thompson et al.)			
	41.	93/23569	29.04.93	WO/PCT (Draper et al.)	<u></u>	ļ	
	42.	93/23057	13.05.93	WO/PCT (Thompson et al.)			
	43.	94/02595	02.07.93	WO/PCT (Sullivan et al.)		-	
	44.	95/04818	04.08.94	WO/PCT (Draper et al.)			
	45.	95/23225	23.02.95	WO/PCT (Stinchcomb et al.)	-		
-	46.	95/13380	10.11.94	WO/PCT (Draper et al.)	4		
	47.	91/03162	05.06.90	WO/PCT (Ross et al.)			
91	48.	98/28317	19.12.97	WO/PCT (Karpeisky et al.)			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

ar	49.	Usman and Cedergren, Trends in Biochem, Sci. 1992, 17, 334-339.
(2)Y	50.	Sproat et al., "An Efficient Method for the Isolation and Purification of Oligoribonucleotides," Nucleosides & Nucleotides 14:255-273 (1995).
877	51.	Gait et al., "Ch. 2 - Oligoribonucleotide synthesis," in <u>Oligonucleotides and Analogues: A Practical Approach</u> , edited by Eckstein, IRL Press, Oxford, pp. 25-48 (1991)
70		

				_
EXAMINER	Jumily	DATE CONSIDERED	13 June 2003	

C.L	4		•	-
Sh	eer	4	Ot	~

FORM	PTO-14	49
(Rev 2	2-321	

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No	٥.
-----------------	----

Serial No.

09/887,182



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

00-830-A

Vargeese et al.

Filing Date:

Group:

June 22, 2001

1623

Я	VX	52.	Weetall et al., 1974, Methods in Enzymology, 34, 59-72.
V	[V]	53.	Van Aerschot et al., 1988, Nucleosides and Nucleotides, 7, 75-90.
		54.	Maskos and Southern, 1992, Nucleic Acids Research, 20, 1679-1684.
		55.	Van Ness et al., 1991, Nucleic Acids Research, 19, 3345-3350.
		56.	Katzhendler et al., "The Effect of Spacer, Linkage and Solid Support on the Synthesis of Oligonucleotides," Tetrahedron 45:2777-2792 (1989)
		57.	Hovinen et al., "Novel Solid Supports for the Preparation of 3'-Derivatized Oligonucleotides: Introduction of 3'-Alkylphosphate Tether Groups Bearing Amino, Carboxy, Carboxamido, and Mercapto Functionalities," <u>Tetrahedron</u> 50:7203-7218 (1994)
		58.	Kitamura et al., 2000, <i>Chem Lett.</i> , 10, 1134-1135.
		59.	Katzhendler et al., "Spacer Effect of the Synthesis of Oligodeoxynucleotides by the Phosphite Method," Reactive Polymers 6:175-187 (1987)
		60.	Katzhendler et al, 1989, <i>Tetrahedron</i> 45, 2777.
		61.	Pon et al., "Derivatization of Controlled Pore Glass Beads for Solid Phase Oligonucleotide Synthesis," BioTechniques 6:768-775 (1988)
-		62.	Greenberg, ., "Photochemical Release of Protected Oligonucleotides Containing 3'-Glycolate Termini," <u>Tetrahedron</u> 51:29-38 (1995)
		63.	Palom et al., 1991, <i>Tetrahedron Lett</i> 34, 2195-2198.
		64.	Pon & Yu, 1997, <i>Tetrahedron Lett</i> 38, 3327-3330.
		65.	Dell-Aquila et al., 1997, Tetrahedron Lett. 38, 5289-5292.
_		66.	Birch-Hirschfeld et al., "A versatile support for the synthesis of oligonucleotides of extended length and scale," Nucleic Acids Research 22:1760-1761 (1994).
		67.	Alul et al., 1991, Nucleic Acids Research 19, 1527-1532.
		68.	Pon, 1993, "Ch. 19 - Solid-Phase Supports for Oligonucleotide Synthesis," in <u>Methods in Molecular Biology, Volume 20: Protocols for Oligonucleotides and Analogs</u> , edited by Agrawal, Humana Press, Inc., Totowa, NJ, pp. 465-497 (1993).
9	VX	69.	Pon et al., 1999, <i>Nucleic Acids Research</i> , 27, 1531-1538.
V	V		

FX	Δ	ΝЛ	١N	ΙF	R

Just of

DATE CONSIDERED

13 JUNE 2003

S	hee	t 5	of	۶

FORM PTO-1449 (Rev. 2-32)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No.

Serial No.

00-830-A

09/887,182



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Vargeese et al.

Filing Date:

Group:

June 22, 2001

1623

On/	70.	Limbach et al., "Summary: the modified nucleosides of RNA," Nucleic Acids Research 22(12):2183-2196 (1994)
010	71.	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," Biochemistry 35:14090-14097 (1996) (volume no mistakenly listed as 6)
	72.	Werner and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," Nucleic Acids Research 23:2092-2096 (1995)
	73.	Hammann et al., ., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," Antisense & Nucleic Acid Drug Development 9:25-31 (1999)
	74.	Cech et al., 1988, 260 JAMA 3030.
	75.	Egholm et al., 1993 Nature 365, 566.
	76.	Stein and Chen, 1993 Science 261, 1004.
	77.	Schmajuk et al., 1999, <i>J. Biol. Chem.</i> , 274, 21783-21789,
	78.	Delihas et al., 1997, Nature, 15, 751-753.
	78.	Stein et al., 1997, Antisense N. A. Drug Dev., 7, 151.
	80.	Crooke, 2000, Methods Enzymol., 313, 3-45.
	81.	Crooke, 1998, Biotech. Genet. Eng. Rev., 15, 121-157.
	82.	Crooke, 1997, Ad. Pharmacol., 40, 1-49.
	83.	Bass, 2001, Nature, 411, 428-429.
	84.	Elbashir et al., 2001, <i>Nature</i> , 411, 494-498.
	85.	Torrence et al., 1993 Proc. Natl. Acad. Sci. USA 90, 1300.
	86.	Silverman et al., 1999, <i>Methods Enzymol.</i> , 313, 522-533.
	87.	Player and Torrence, 1998, Pharmacol. Ther., 78, 55-113.
SYX	88.	Duval-Valentin et al., 1992 Proc. Natl. Acad. Sci. USA 89, 504.

EXAMINER

DATE CONSIDERED

13 JUNE 2003

Sheet 6 of 8

FORM	PTO-	1449
(Rev. 2	2-321	

U.S. Department of Commerce Patent and Trademark Office

Atty.	Docket	No.
, .		

Serial No.

00-830-A

09/887,182



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Vargeese et al.

Filing Date:

Group:

June 22, 2001

1623

00	89.	Fox, 2000, <i>Curr. Med. Chem.</i> , 7, 17-37.
10 1	90.	Praseuth et al., 2000, <i>Biochim. Biophys. Acta</i> , 1489, 181-206.
	94.	Sullenger et al., 1990, Cell, 63, 601-608.
	92.	Gold et al., 1995, <i>Annu. Rev. Biochem.</i> , 64, 763.
	93.	Brody and Gold, 2000, J. Biotechnol., 74, 5.
	94.	Sun, 2000, Curr. Opin. Mol. Ther., 2, 100.
	95.	Kusser, 2000, J. Biotechnol., 74, 27.
	96.	Hermann and Patel, 2000, Science, 287, 820.
	97.	Jayasena, 1999, Clinical Chemistry, 45, 1628.
•	98.	Scaringe et al., Nucleic Acids Res. 1990, 18, 5433-5441.
	90.	Usman et al., 1987, <i>J. Am. Chem. Soc.</i> , 109, 7845.
	100	Scaringe et al., 1990, Nucleic Acids Res., 18, 5433.
	101	Wincott et al., 1995, Nucleic Acids Res. 23, 2677-2684 Wincott et al., 1997, Methods Mol. Bio., 74, 59
	102	Christoffersen, Nature Biotech, 1997, 2, 483-484.
	103	Orgel, 1979, <i>Proc. R. Soc. London</i> , B 205, 435.
	104	Joyce, 1989, <i>Gene</i> , 82, 83-87.
	105	Beaudry et al., 1992, <i>Science</i> 257, 635-641.
	106	Joyce, 1992, Scientific American 267, 90-97.
	107	Breaker et al., 1994, TIBTECH 12, 268.
<u>γγ</u>	108	Bartel et al., 1993 Science 261:1411-1418.

EXAMINER	ΕX	А١	M١	N	ΕF	₹
----------	----	----	----	---	----	---

Just

DATE CONSIDERED

13 JUNE 2003

1623

June 22, 2001

			Sheet 7 of 8	
FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Offic	Atty. Docket No.	S rial No. 09/887,182	
O 1 P & VC 5 8	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
APR U 9 ZULE 88	(Odd deveral directs if freedastily)	Applicant: Vargeese et al.		
		Filing Date:	Group:	

0.	****						
-XXX	109	Szostak, 1993, TIBS 17, 89-93.					
4349	110	Kumar et al., 1995, FASEB J., 9, 1183.					
979	111	Breaker, 1996, Curr. Op. Biotech., 7, 442.					
84	112	Santoro et al., 1997, Proc. Natl. Acad. Sci., 94, 4262.					
911	113	Tang et al., 1997, RNA 3, 914.					
20	114	Nakamaye Y Eckstein, 1904, supra. incomplete citedron					
	115	Long & Uhlenbeck, 1994, supra. in complete citation					
	116	Long & Uhlenbeck, 1994, supra. incomplete citation Ishizaka et al., 1995, supra. incomplete citation					
9/1	117	Vaish et al., 1997, Biochemistry 36, 6495.					
<i>U</i> <i>V</i>	118	Zaug et al., 324, Nature 429 1986.					
	118	Uhlenbeck, 1987 Nature 328, 596.					
	120	Kim et al., 84 <i>Proc. Natl. Acad. Sci. USA</i> 8788, 1987.					
	121	Dreyfus, 1988, Einstein Quart. J. Bio. Med., 6, 92.					
	122	Haseloff and Gerlach, 334 Nature 585, 1988.					
	Jefferies et al., 17 Nucleic Acids Research 1371, 1989.						
	124	Usman & McSwiggen, 1995 Ann. Rep. Med. Chem. 30, 285-294.					
	125	Christoffersen and Marr, 1995 J. Med. Chem. 38, 2023-2037.					
	126	Warashina et al., 1999, Chemistry and Biology, 6, 237-250.					
	127	Woo-Pong, Nov. 1994, <i>BioPharm</i> , 20-33.					
(VV)	128	Mukhopadhyay & Roth, 1996, Crit. Rev. in Oncogenesis 7, 151-190.					
VI							

EXAMINER Jupie	DATE CONSIDERED 13 JUNE 2003

FORM PTO-1449 (Rev. 2-32)

U.S. Department of Commerce Patent and Trademark Office

Atty. Dock t No.

Serial No.

09/887,182

) (I

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

00-830-A

Vargeese et al.

Filing Date:

Group:

June 22, 2001

1623

2	1	129	Mitra et al., 1996, <i>Proc Nat Acad Sci USA</i> 93, 6780-6785.					
		134	Perrault et al., 1990 <i>Nature</i> 344, 565.					
		131	Picken et al., 1991, <i>Science</i> 253, 314.					
		132	Usman and Cedergren, 1992, Trends in Biochem. Sci. 17, 334-339.					
		133	Beigelman et al., 1995, <i>J. Biol. Chem.</i> , 270, 25702.					
		134	Karpeisky et al., 1998, Tetrahedron Lett., 39, 1131.					
		135	Earnshaw and Gait, 1998, Biopolymers (Nucleic acid Sciences), 48, 39-55.					
		136	Verma and Eckstein, 1998, <i>Annu. Rev. Biochem.</i> , 67, 99-134.					
		137	Burlina et al., 1997, <i>Bioorg. Med. Chem.</i> , 5, 1999-2010.					
		138	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <u>Methods in</u> Enzymology 211:3-19 (1992)					
		139	Beaucage and Iyer, 1993, Tetrahedron 49, 1925.					
		140	Hunziker and Leumann, 1995, Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods, VCH, 331-417, and Mesmaeker et al., 1994, Novel Backbone Replacements for Oligonucleotides, in Carbohydrate Modifications in Antisense Research, ACS, 24-39.					
8	χ	141	Nathans et al., 1975 Ann. Rev. Biochem. 44: 273.					

EX	Α	٨	11	Ν	Ε	R
----	---	---	----	---	---	---

Joseph S

DATE CONSIDERED

13 JUNE 2003